RSV vaccination at 32 to 36 weeks gestation to prevent RSV in infant

This indication refers to maternal immunization administered to pregnant individuals between 32 0/7 and 36 6/7 weeks of gestation to confer passive immunity to their infants from birth through six months of age

This indication refers to maternal immunization administered to pregnant individuals between 32 0/7 and 36 6/7 weeks of gestation to confer passive immunity to their infants from birth through six months of age The target condition is lower respiratory tract disease caused by respiratory syncytial virus, an enveloped RNA pneumovirus that primarily damages the infant respiratory system In young infants, infection predominantly targets the bronchiolar epithelial cells, leading to airway inflammati...

The target condition is lower respiratory tract disease caused by respiratory syncytial virus, an enveloped RNA pneumovirus that primarily damages the infant respiratory system In young infants, infection predominantly targets the bronchiolar epithelial cells, leading to airway inflammation, epithelial necrosis, mucus plug formation, and impaired gas exchange

The target condition is lower respiratory tract disease caused by respiratory syncytial virus, an enveloped RNA pneumovirus that primarily damages the infant respiratory system In young infants, infection predominantly targets the bronchiolar epithelial cells, leading to airway inflammation, epithelial necrosis, mucus plug formation, and impaired gas exchange Clinical manifestations range from mild upper respiratory catarrh to severe bronchiolitis and pneumonia, frequently characterized by tachy...

Clinical manifestations range from mild upper respiratory catarrh to severe bronchiolitis and pneumonia, frequently characterized by tachypnea, wheezing, intercostal retractions, cyanosis, apnea, and acute respiratory failure